The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi,
I sold some 4D today was 260% up and already on free carry. Put it in here, shows as sell, but that’s the spread and lse mid point algorithm.
Investing in therapeutics is massive risk, investing in testers and data for therapeutics is less risk and can still have significant upside.
Watch your SNG, imo no deal and then they will need cash. I hold a free carry there. Won’t sell that but be aware.
Also cash is still a question here as we don’t know revs yet but following the words from Adam about significant volumes that =‘s money. Even if they did raise it wouldn’t imo be too deep a discount and the stock needs liquidity. There will be plenty of buyers and if dips I will defo sell elsewhere and buy more here as we know what’s ahead in Q121. When the news gets out I will offload a few. Just gotta DYOR and be patient.
Atb
Trek
Trek,
Thanks for the posts and comments. I am surprised there is not more interest in ONC but it gives the opportunity to buy more shares (latest 5k buy today shown as a sell as happened yesterday). Mcap around £100m with the number and quality of collaborations growing ONC is quietly moving ahead. There is also much less SP volatility which bedevils other holdings. I will buy more but don't want to sell any of largest holdings in Avacta or SNG yet as they also have more news coming. Sorry to see 4D slipped today but I will look at that again.
Worth a listen from 9mins to 19mins or 15mins to 19mins....
“Adam talks to Professor Chris Molloy, CEO of the UK's Medicines Discovery Catapult, the National Research Technology Facility supporting the sector by industrialising and driving the adoption of new approaches to discovering medicines.
Most recently, Chris has been responsible for establishing and running the Lighthouse Labs, the biggest diagnostic lab in British history. Developed in partnership with AstraZeneca and GSK, these labs provide diagnostics infrastructure, which have the capability to test tens of thousands of patient samples each day for Coronavirus.
Chris talks about the herculean task he and his team had in setting up the LightHouse Labs, what he is most proud of and with the lab infrastructure now in place, what are the opportunities to test, trace, and better stratify patients into various forms of therapies in the United Kingdom.”
https://www.lse.co.uk/ShareChat.asp?ShareTicker=ONC&share=Oncimmune&thread=12DE2595-893B-4952-B309-67DF611EAFD7&reply=true
Trek
Hi David,
You can add 4D to that list recently!
I guess it takes a while for this to sink in. It doesn’t help that it is yet another deal where we don’t have the finances. One has to read between the lines and use one’s own judgement. The Lighthouse Labs project is funded. Collaborations are in place. See vids at end of RNS. Also why would UK plc want to part finance something cognisant of its clinical and patient need for some time to come. There has also been lots in the press around ‘long covid’ not to mention ‘bad press’ of late.
I was fully invested so had to sell some SNG to add here. SNG is now on a 100% free carry for me and that is significantly up! I expect to see the same here soon.
There is a massive news flow for ONC now and into the new year and NavigAID will be up and running in 6months with all the run up news. It’s pretty staggering what’s in the pipeline here!
ATB
Trek
Trek,
More news came more quickly than expected. Interesting to see what happens and whether this RNS creates much more interest and more commentators. It used to be like this on Avacta, SNG and VAL boards but most comments on those now are not worth anything.
RNS,Government grant
Not just you... I’m just doing that lights and bushels thing. Seem to have mislaid my bushel at the moment... :)
Seriously though, thanks to all here for the well informed and well researched posts. I can’t have much to add to them, but I will be extremely grateful if things go the way we hope they will. When they do!
Trek....Exactly enjoy the peace and quiet before the crowd arrives. I am slowly scaling in here and busy watching the videos and reading up on the company so a little delay before the crowd arrives would be appreciated!!!
Experienced the same thing at SNG when I was buying early January nice a quiet under the radar. Now I barely check in on the board as so many posts to dredge through.....thankfully DDDD still seems fairly civil and positive.
Have a good weekend all....or is that just the two of us!!!
Since Feb we have gone from 31p to 140p. We are now well above the 2017 IPO price. We have conducted the biggest phase three trial ever on lung cancer detection and have a proven test that can detect the disease FROM 4 years in advance and that tech is played across to liver and soon other cancers.
We have a massive pipeline of deals including Russian and China pending. We have access and sales to UK. USA , Europe etc gosh I could go on and we’re even now on an AIM company of the year shortlist!
Even the director options don’t kick in till two quid!
Why oh why is it that punters on AIM can’t dyor and find companies like this and gradually buy in to them. They seem to arrive after the event get and spiked and turn a bb to acrimony!
Well I guess the few of us here just as well enjoys peace while it lasts!
Trek
Just realised I was talking to a bot. Here’s a proper link
https://www.ii.co.uk/analysis-commentary/who-will-win-big-years-aim-awards-ii513583?utm_source=newsletter&utm_medium=email&utm_campaign=Weekend_round_up_newsletter_250920&utm_content=newsletter&spMailingID=10635647&spUserID=MTI1MDU0MTk3NzM1S0&spJobID=1594279168&spReportId=MTU5NDI3OTE2OAS2
Trek
Ha you beat me to it. I was just reading in garden!
Oncimmune (LSE:ONC) has not been on this shortlist before but it has previously been up for the best technology award. Earlier this year, UK-based NICE and peer reviews have provided positive endorsement for EarlyCDT Lung cancer screening and detection product and this has helped the share price to bounce back.
Trek
Oncimmune inks collaboration with Genentech that broadens the "commercial footprint” of its ImmunoINSIGHTS service business
"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” said chief executive, Dr Adam Hill
Oncimmune Holdings PLC (AIM:ONC) said it has signed a collaboration to profile samples from Genentech's rheumatology clinical trials, broadening the "commercial footprint” of its ImmunoINSIGHTS service business.
Oncimmune’s NavigAID arrays will be used to characterise the auto-antibody profiles of patients taking part in studies for rheumatological diseases, including the autoimmune disease lupus.
Following the project’s completion, Genentech, which is now part of Swiss giant Roche, has the option to expand the contract to profile additional samples.
"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” Oncimmune chief executive, Dr Adam Hil said in a statement.
“This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in the full-year 2021 and provides another opportunity to show how our NavigAID technology can assist partners in increasing their ability to better assess where their medicines could make an impact,” he added.
https://www.proactiveinvestors.co.uk/companies/news/929752/oncimmune-inks-collaboration-with-genentech-that-broadens-the--commercial-footprint-of-its-immunoinsights-service-business-929752.html
Trek
Wow over £600k of buys gone through close together! That takes some doing getting those with this stock!
Re other Pharma. Got a few on the watchlist waiting for price entry but my biggest holding is DDDD & SNG in the pure biotech space and ORPH, AVCT & GDR which are more test orientated and small positions in IQAI and SYM.
The first four I have free or nearly free carries having traded them so what’s left can ride now. I did buy ERGO, another quiet stock and sold after it did nothing no matter how good the news was! It them went on to bag after I sold!
I also held SAR, it was a dog and I sold at a loss, twice! It’s not easy. AVCT and SNG could go either way now primarily because of time taken to get products out. Research is key. ONC are unique insofar as the have a niche with high barriers to entry and are driving revs. The risk is with the big Pharma that use their tools. A bit like selling shovels to gold prospectors!
Atb
Trek
Trek,
Comments appreciated and it all looks promising. This company seems to be low profile compared to peers but has a lot of potential based on current Mcap and their pipeline. Hopefully ONC are on the cusp of greater success.
In looking at micro pharmas have you any other targets - mine is N4.
Hi David,
Totally agree re revs, I posted similar earlier. I think Adam has given us as much a hint as possible though with ‘ALREADY SUBSTANTIAL PIPELINE...’.
It’s quite possible Roche would be interested. We are only 90m mcap and a world leader in this tech. The ability to detect several cancers up to 4 years in advance and use the proprietary platforms to target therapies saving huge costs is a ‘must have’!
The SeroTag platform has over 8000 autoantibodies listed and responses. Lung and liver cancer detection. RA and now developing Lupus. Imagine when ovarian, breast and prostrate cancer is added!
I have been trying to work out who the big 4 Pharmas are. Roche we know, I expect others are MSD (Merck) and BMS (Bristol Myers Squibb), the 4 I haven’t figured yet but you can include NHS as a virtual 5th!
Re finance from last trading update we know cash is ok as expect £4.2m left at year end but it’s the revenue conversion that we need to see for a sp rerate..
“The Board is confident in reporting revenue in line with market expectations for FY 2020. Cash at year end is expected to be approximately £4.2 million and net debt of approximately £3.1 million, reflecting the ongoing cost reduction programme highlighted in the Half Year Report on 12 February 2020.
The contracts signed within the ImmunoINSIGHTS business, and agreements signed with strategic biopharmaceutical partners to develop commercial companion diagnostic devices, provide the Board with confidence that the Group is well positioned to have a strong start to FY 2021.”
So agree how much money is it worth?
However, I do see this bagging again, several times from here. Two big newt term inflection points are the results from the China and Russia EarlyCDT lung trials. Remember Russia includes the former commonwealth territories, Georgia, Turkmenistan, Kazakhstan etc. Why would the validation fail given its use in US, UK, Germany etc!
China and Russia are huge markets. The director options are also completely aligned and don’t kick in until £2.
Proactive today...
https://www.proactiveinvestors.co.uk/companies/news/929752/oncimmune-inks-collaboration-with-genentech-that-broadens-the--commercial-footprint-of-its-immunoinsights-service-business-929752.html
ATB
Trek
This might be seen as an additional deal and the main issue for investors or new investors, is lack of information on the value or earnings from the collaborations. It may be commercially sensitive and only become apparent when the next results are released but investment decisions need to be based on more than we have available. News on Early lung test wider usage in NHS and other countries would be the other spur to invest. Is a take over by Roche a possibility?
Not quite the news I was expecting but if you consider Genentech is a major US biotech and a subsidiary of Roche this is now the third major collaboration with Roche! That is a significant endorsement of ONC’s proprietary platforms, SeroTag, immunoINSIGHTS and NavigAID.
I don’t think the market gets this yet....
ImmunoINSIGHTS is underpinned by our proprietary high throughput immunogenic protein library, one of the largest in the world, allowing for more than 95% of human antigens to be utilised for profiling autoantibodies in patients receiving or about to receive treatment.
With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early stage start-ups, leading academic groups, and not-for-profit companies.
The autoantibody biomarker class is increasingly being recognised as a powerful tool and critical biological mediator including in cancer and autoimmune disease.
Autoantibodies are specific and reflective of disease state, indicators of the activation of both the B and T cell sides of the adaptive immune system, soluble and detectable in low volumes of blood, and raised at the earliest stages of disease.
Used to stratify patients into clinically relevant sub-groups, our ImmunoINSIGHTS service can be utilised to:
Predict response to treatment and immune-related adverse events (irAEs)[1];
Predict the severity of symptoms in infectious disease (COVID-19);
Identify novel target molecules;
Detect treatment-specific immune excitation (e.g. Heating of cold tumours)[2],[3];
Predict off-target effects.
https://oncimmune.com/immunoinsights
And so good of Dr Adam to give us a revenue hint in his CEO blurb.... “....This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in FY2021....”
Gonna be a big deal this one. A test platform that can detect cancer four years in advance and is being used by 4 major Pharma companies to target therapies!
Trek
4 major deals signed, RNS dates
4...2nd Sept - Autoantibodies profiling using SeroTag. Top 10 Pharma.
......10th Aug - EarlyCDT lung in use in NHS (ITV)
3.....27th July - Substantial contract expansion with Roche for autoantibodies profiling using SeroTag.
......8th July Early Rheumatoid arthritis (RA) detection using autoantibodies
......1st July, EarlyCDT lung being sold in Brazil
2.....21st May EarlyCDT lung contract signed with major Pharma.
1......12th May. SeroTag Collaboration Agreement Signed with Leading US Biopharmaceutical Company
If you include NHS usage that’s 5 major deals.
14th May RNS....ASCO presentation.
“The featured presentation will review data assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab, which have been analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag®. The data identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events ("irAEs").”
Pembrolizumab trade name is Keytruda, which owned by Merck (MSD). They are also working with 4D Pharma using the MicroRX platform matching LBT. The ONC autoantibodies Test would be complimentary. My money is Merck (MSD) is the US biopharmaceutical Co.
Ipilimumab, sold under the brand name Yervoy, owned by BMS also US
Nivolumab, sold under the brand name Opdivo, owned by BMS.
So guess work is Merck, BMS in the US working with Biodesix and also Roche which we know.
With commercial distribution of earlyCDT Lung in UK, US, Brazil (Valentech), Spain (Sabartech) and other European countries with Russia (R-Pharm + independent states) & China (Genostics) there has to be some huge revenue upsides here!
That is just for EarlyCDT Lung. Add Early, Liver, prostate, ovarian, breast cancer detection and Rheumatoid Arthritis to the platform and this is developing into a huge opportunity!
So much news due!
Trek